Alexis A. Thompson - 17 Mar 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role: Director
Signature: /s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 17 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 18 Mar 2022, 18:58:57 UTC
Previous filing: 21 Jun 2021
Next filing: 16 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GBT	Common Stock	Options Exercise		+2,400			2,400	17 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GBT	Restricted Stock Units	Options Exercise	$0	-2,400	-33%	$0.000000	4,800	17 Mar 2022	Common Stock	2,400		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2	The shares of Common Stock underlying the RSUs vest in three equal annual installments after March 17, 2021, so long as the Reporting Person continues as a board member of the Issuer through each vesting date. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).

Content

Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

The shares of Common Stock underlying the RSUs vest in three equal annual installments after March 17, 2021, so long as the Reporting Person continues as a board member of the Issuer through each vesting date. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).